超快速乳腺MRI预测新辅助治疗后病理反应的前瞻性评估
前瞻性单中心研究纳入50例接受新辅助化疗的非转移性浸润性乳腺癌女性,评估初始超快速动态增强MRI的半定量灌注参数与病理完全缓解的关系。洗入斜率(WIS)>1.6%/秒、HER2阳性和肿瘤浸润淋巴细胞>10%是pCR的独立预测因素,三因素模型AUC为0.92。WIS评估可能用于预测乳腺癌患者的pCR。
要点
- WIS>1.6%/秒预测pCR的敏感度为94%(17/18),特异度为59%(19/32)。
- WIS>1.6%/秒、HER2阳性和TIL>10%是pCR的独立预测因素。
- 三因素模型(WIS、TIL、HER2)预测pCR的AUC为0.92(95%CI:0.84,0.99)。
核心结论
- 初始超快速动态增强MRI的WIS评估可能用于预测乳腺癌患者的病理完全缓解(pCR)。
研究设计与样本
- 前瞻性单中心研究,纳入2020年12月至2021年8月间连续接受新辅助化疗后手术的非转移性浸润性乳腺癌女性50例(平均年龄49岁±12)。
诊断标准与关键数值
- WIS截断值1.6%/秒预测pCR的敏感度为94%(17/18),特异度为59%(19/32)。
- WIS>1.6%/秒预测pCR的OR为8.4(95%CI:1.5,48.2;P=0.02)。
- HER2阳性预测pCR的OR为6.3(95%CI:1.5,27.4;P=0.01);TIL>10%预测pCR的OR为6.9(95%CI:1.3,37.7;P=0.03)。
- 三因素模型(WIS、TIL、HER2)预测pCR的AUC为0.92(95%CI:0.84,0.99)。
- HER2阳性亚组中WIS>1.6%/秒与更高pCR率相关(OR,21.7[95%CI:1.8,260.6];P=0.02);Luminal HER2阴性和三阴性乳腺癌中WIS>1.6%/秒与低RCB相关(OR,11.0[95%CI:1.1,106.4];P=0.04)。
临床应用与阅片要点
- 初始超快速动态增强MRI计算的WIS可能用于预测乳腺癌新辅助化疗后的pCR。
- WIS>1.6%/秒可能用于区分HER2阳性乳腺癌中pCR率不同的两个亚组。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Ultrafast dynamic contrast-enhanced (DCE) MRI parameters are associated with breast cancer aggressiveness. However, the role of these parameters as predictive biomarkers for pathologic response after neoadjuvant chemotherapy (NAC) has been poorly investigated. Purpose To assess whether semiquantitative perfusion parameters calculated at initial ultrafast DCE MRI are associated with early prediction for pathologic response after NAC in participants with breast cancer. Materials and Methods This prospective single-center study included consecutive women with nonmetastatic invasive breast cancer treated with NAC followed by surgery who underwent initial ultrafast DCE MRI between December 2020 and August 2021. Six semiquantitative ultrafast DCE MRI parameters were calculated for each participant from the fitted time-signal intensity curve. Multivariable logistic regression was used to identify independent predictors of pathologic complete response (pCR) and residual cancer burden (RCB). Results Fifty women (mean age, 49 years ± 12 [SD]) were included in the study; 20 achieved pCR and 25 achieved low RCB (RCB-0 and I). A wash-in slope (WIS) cutoff value of 1.6% per second had a sensitivity of 94% (17 of 18 participants) and a specificity of 59% (19 of 32 participants) for pCR. A WIS of more than 1.6% per second (odds ratio [OR], 8.4 [95% CI: 1.5, 48.2]; P = .02), human epidermal growth factor receptor 2 (HER2) positivity (OR, 6.3 [95% CI: 1.5, 27.4]; P = .01), and tumor-infiltrating lymphocytes of more than 10% (OR, 6.9 [95% CI: 1.3, 37.7]; P = .03) were independent predictive factors of pCR. The area under the receiver operating characteristic curve of the three-component model, which included WIS, tumor-infiltrating lymphocytes, and HER2 positivity, was 0.92 (95% CI: 0.84, 0.99). A WIS of more than 1.6% per second was associated with higher pCR rates in the HER2-positive (OR, 21.7 [95% CI: 1.8, 260.6]; P = .02) breast cancer subgroup. For luminal HER2-negative and triple-negative breast cancers, a WIS of more than 1.6% per second was associated with low RCB (OR, 11.0 [95% CI: 1.1, 106.4]; P = .04). Conclusion The wash-in slope (WIS) assessment at initial ultrafast dynamic contrast-enhanced MRI may be used to predict pathologic complete response (pCR) in participants with breast cancer. The WIS value was used to identify two subsets of human epidermal growth factor receptor 2-positive cancers with distinct pCR rates. © RSNA, 2022 Online supplemental material is available for this article. See also the editorial by Lee and Moy in this issue.
引用
- Ramtohul, Tescher, Vaflard, et al. Prospective Evaluation of Ultrafast Breast MRI for Predicting Pathologic Response after Neoadjuvant Therapies. Radiology. 2022. PMID: 35880977. doi:10.1148/radiol.220389
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。